| Drug General Information |
| Drug ID |
D0H6OS
|
| Former ID |
DNC004248
|
| Drug Name |
Geldanamycin-estradiol hybrid
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
mRNA of HER2 |
Target Info |
Inhibitor |
[1]
|
|---|
| Estrogen receptor beta |
Target Info |
Inhibitor |
[1]
|
| Heat shock protein HSP 90 |
Target Info |
Inhibitor |
[1]
|
| Estrogen receptor |
Target Info |
Inhibitor |
[1]
|
| Heat shock protein HSP90 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
ErbB signaling pathway
|
|
Calcium signaling pathway
|
|
HIF-1 signaling pathway
|
|
Focal adhesion
|
|
Adherens junction
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Prostate cancer
|
|
Bladder cancer
|
|
Non-small cell lung cancer
|
|
Central carbon metabolism in cancerhsa04915:Estrogen signaling pathway
|
|
Prolactin signaling pathwayhsa04141:Protein processing in endoplasmic reticulum
|
|
PI3K-Akt signaling pathway
|
|
Antigen processing and presentation
|
|
NOD-like receptor signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Estrogen signaling pathway
|
|
Prostate cancerhsa04915:Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Endocrine and other factor-regulated calcium reabsorption
|
|
NetPath Pathway
|
TCR Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
TCR Signaling PathwayNetPath_25:FSH Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
PANTHER Pathway
|
Cadherin signaling pathway
|
|
EGF receptor signaling pathway
|
|
Pathway Interaction Database
|
ErbB4 signaling events
|
|
ErbB2/ErbB3 signaling events
|
|
ErbB receptor signaling network
|
|
a6b1 and a6b4 Integrin signaling
|
|
Validated targets of C-MYC transcriptional repressioner_nongenomic_pathway:Plasma membrane estrogen receptor signaling
|
|
Validated nuclear estrogen receptor beta network
|
|
Validated nuclear estrogen receptor alpha networkhdac_classii_pathway:Signaling events mediated by HDAC Class II
|
|
Validated targets of C-MYC transcriptional activation
|
|
Integrin-linked kinase signaling
|
|
LKB1 signaling events
|
|
Regulation of Telomerase
|
|
Glucocorticoid receptor regulatory network
|
|
Class I PI3K signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
Regulation of Androgen receptor activity
|
|
Integrins in angiogenesis
|
|
Hypoxic and oxygen homeostasis regulation of HIF-1-alpha
|
|
VEGFR1 specific signals
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Class I PI3K signaling events mediated by Aktsmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by HDAC Class II
|
|
Plasma membrane estrogen receptor signaling
|
|
ATF-2 transcription factor network
|
|
AP-1 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Validated nuclear estrogen receptor alpha network
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
FOXA1 transcription factor network
|
|
PathWhiz Pathway
|
Phosphatidylinositol Phosphate Metabolism
|
|
Reactome
|
SHC1 events in ERBB2 signaling
|
|
PLCG1 events in ERBB2 signaling
|
|
PIP3 activates AKT signaling
|
|
GRB2 events in ERBB2 signaling
|
|
PI3K events in ERBB2 signaling
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
Sema4D induced cell migration and growth-cone collapse
|
|
RAF/MAP kinase cascadeR-HSA-383280:Nuclear Receptor transcription pathwayR-HSA-1236382:Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
|
|
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
|
|
Regulation of actin dynamics for phagocytic cup formation
|
|
eNOS activation
|
|
Regulation of PLK1 Activity at G2/M Transition
|
|
Attenuation phase
|
|
HSF1-dependent transactivation
|
|
Loss of Nlp from mitotic centrosomes
|
|
Recruitment of mitotic centrosome proteins and complexes
|
|
Loss of proteins required for interphase microtubule organization?from the centrosome
|
|
EPHA-mediated growth cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
VEGFR2 mediated vascular permeability
|
|
Anchoring of the basal body to the plasma membrane
|
|
Constitutive Signaling by EGFRvIIIR-HSA-1251985:Nuclear signaling by ERBB4
|
|
Nuclear Receptor transcription pathway
|
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
|
ErbB Signaling Pathway
|
|
EGF/EGFR Signaling Pathway
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
Bladder Cancer
|
|
Signaling by ERBB2
|
|
Integrated Pancreatic Cancer Pathway
|
|
Signaling Pathways in Glioblastoma
|
|
Leptin signaling pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
Semaphorin interactionsWP706:SIDS Susceptibility Pathways
|
|
Ovarian Infertility Genes
|
|
Nuclear ReceptorsWP2884:NRF2 pathway
|
|
Nuclear Receptors Meta-Pathway
|
|
Aryl Hydrocarbon Receptor Pathway
|
|
Binding and Uptake of Ligands by Scavenger Receptors
|
|
Fcgamma receptor (FCGR) dependent phagocytosis
|
|
Influenza Life Cycle
|
|
EBV LMP1 signaling
|
|
Aryl Hydrocarbon Receptor
|
|
Corticotropin-releasing hormone
|
|
TNF alpha Signaling Pathway
|
|
Arylhydrocarbon receptor (AhR) signaling pathway
|
|
Signaling by EGFR
|
|
Semaphorin interactions
|
|
Mitotic G2-G2/M phases
|
|
Metabolism of nitric oxide
|
|
NOD pathwayWP712:Estrogen signaling pathway
|
|
Estrogen Receptor Pathway
|
|
Signaling by ERBB4
|
|
JAK/STAT
|
|
Integrated Breast Cancer Pathway
|
|
Nuclear Receptors
|
| References |
| REF 1 | Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8.Synthesis and evaluation of geldanamycin-estradiol hybrids. |
|---|
